Immune checkpoint inhibitors revolutionize the treatment of malignant melanoma – insights from the Cancer Registry Saxony
Introduction: The introduction of immune checkpoint inhibitors (ICI) in 2011 symbolizes a paradigm shift in cancer treatment. Especially in metastatic malignant melanoma, the first cancer entity for which ICIs were approved [ref:1], significant better treatment results have been described. [for full text, please go to the a.m. URL]
Institutions
- National Cancer Registry (IE)
Publication Details
- Journal
- German Medical Science (German Research Foundation)
- Published
- 2025-11-03
- DOI
- https://doi.org/10.3205/25gmds087
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00